These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 26819503)

  • 21. The state of therapy modalities in clinic for biliary tract cancer.
    Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
    Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholangiocarcinoma: new perspectives for new horizons.
    Rimini M; Puzzoni M; Pedica F; Silvestris N; Fornaro L; Aprile G; Loi E; Brunetti O; Vivaldi C; Simionato F; Zavattari P; Scartozzi M; Burgio V; Ratti F; Aldrighetti L; Cascinu S; Casadei-Gardini A
    Expert Rev Gastroenterol Hepatol; 2021 Dec; 15(12):1367-1383. PubMed ID: 34669536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials.
    Simile MM; Bagella P; Vidili G; Spanu A; Manetti R; Seddaiu MA; Babudieri S; Madeddu G; Serra PA; Altana M; Paliogiannis P
    Medicina (Kaunas); 2019 Feb; 55(2):. PubMed ID: 30743998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
    Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
    Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future.
    Rizzo A; Ricci AD; Cusmai A; Acquafredda S; De Palma G; Brandi G; Palmiotti G
    Curr Oncol; 2022 Jan; 29(2):551-564. PubMed ID: 35200550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting cancer stem cells in cholangiocarcinoma (Review).
    Mcgrath NA; Fu J; Gu SZ; Xie C
    Int J Oncol; 2020 Aug; 57(2):397-408. PubMed ID: 32468022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted therapy for biliary tract cancers.
    Faris JE; Zhu AX
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):326-36. PubMed ID: 22318523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of novel biologics in biliary cancers.
    Jordan E; Braghiroli MF; Lowery MA
    Minerva Gastroenterol Dietol; 2016 Dec; 62(4):325-339. PubMed ID: 27576672
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma.
    King G; Javle M
    Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
    Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular aspects of cholangiocarcinoma.
    Kiguchi K
    J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):371-9. PubMed ID: 24420749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted therapies in advanced biliary tract cancers-a narrative review.
    LaPelusa M; Heumann T; Goff L; Agarwal R
    Chin Clin Oncol; 2023 Apr; 12(2):14. PubMed ID: 36946186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coming of a precision era of the staging systems for intrahepatic cholangiocarcinoma?
    Cheng Z; Lei Z; Shen F
    Cancer Lett; 2019 Sep; 460():10-17. PubMed ID: 31212000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs.
    Sipra QUAR; Shroff R
    Expert Opin Investig Drugs; 2021 Apr; 30(4):281-284. PubMed ID: 33228417
    [No Abstract]   [Full Text] [Related]  

  • 37. Integrating cytotoxic, targeted and immune therapies for cholangiocarcinoma.
    Merters J; Lamarca A
    J Hepatol; 2023 Mar; 78(3):652-657. PubMed ID: 36400328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma.
    Ishige K; Shoda J; Kawamoto T; Matsuda S; Ueda T; Hyodo I; Ohkohchi N; Puri RK; Kawakami K
    Int J Cancer; 2008 Dec; 123(12):2915-22. PubMed ID: 18798553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.
    Voss JS; Holtegaard LM; Kerr SE; Fritcher EG; Roberts LR; Gores GJ; Zhang J; Highsmith WE; Halling KC; Kipp BR
    Hum Pathol; 2013 Jul; 44(7):1216-22. PubMed ID: 23391413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice.
    Kasuga A; Semba T; Sato R; Nobusue H; Sugihara E; Takaishi H; Kanai T; Saya H; Arima Y
    Cancer Sci; 2021 May; 112(5):1822-1838. PubMed ID: 33068050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.